Orchestra BioMed highlights $500 million-plus annual royalty potential from Medtronic-partnered AVIM pacemaker therapy
OBIO•Funding and runway
Strategic partners invested and paid more than $185 million; cash runway projected through 2027.
Medtronic partnership economics
Medtronic partnership grants OBIO an uncapped double-digit royalty-based revenue share on each AVIM Therapy-enabled device sold.
Royalty partnership strategy and AVIM Therapy timeline
Orchestra BioMed outlined a capital-efficient royalty partnership strategy built around AVIM Therapy and Virtue SAB in cardiovascular markets.
AVIM Therapy BACKBEAT pivotal trial targeted enrollment completion in Q3 2026; primary endpoint data targeted for Q2 2027.
Timeline flagged FDA review of a PMA submission in 2H 2027; potential FDA approval in 1H 2028; potential OUS launches in 2H 2028.
